Jacobsen Capital Management Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Jacobsen Capital Management grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,258 shares of the company’s stock after buying an additional 103 shares during the period. Eli Lilly and Company accounts for approximately 0.5% of Jacobsen Capital Management’s holdings, making the stock its 19th biggest holding. Jacobsen Capital Management’s holdings in Eli Lilly and Company were worth $1,139,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Tidemark LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $32,000. Frank Rimerman Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth $37,000. Finally, St. Johns Investment Management Company LLC increased its holdings in Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after purchasing an additional 37 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 22,206 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $822.11, for a total transaction of $18,255,774.66. Following the completion of the sale, the insider now owns 98,401,604 shares of the company’s stock, valued at approximately $80,896,942,664.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 22,206 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $822.11, for a total transaction of $18,255,774.66. Following the completion of the transaction, the insider now owns 98,401,604 shares in the company, valued at approximately $80,896,942,664.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders sold a total of 1,122,141 shares of company stock valued at $991,938,411 over the last 90 days. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $4.65 during mid-day trading on Friday, hitting $958.82. The stock had a trading volume of 247,840 shares, compared to its average volume of 3,085,240. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a market cap of $911.27 billion, a PE ratio of 141.38, a PEG ratio of 1.81 and a beta of 0.41. The company’s fifty day simple moving average is $884.83 and its two-hundred day simple moving average is $812.10.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,023.00 price objective on shares of Eli Lilly and Company in a research report on Friday, July 5th. Barclays boosted their target price on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price target for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $956.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.